Flat session for AstraZeneca stock — mixed oscillators temper bullish trend

Traders Union
All News
Financial News
AstraZeneca rises 0.13% today

Highlights

AstraZeneca updated its clinical pipeline, announcing positive mid-stage trial results for AZD1163 in rheumatoid arthritis and progress in a real-world study on paroxysmal nocturnal hemoglobinuria in China.
AstraZeneca and Daiichi Sankyo jointly applied for a second EU approval of Datopotamab Deruxtecan, advancing their oncology portfolio in the region.
AstraZeneca disclosed an internal share transfer by Non-Executive Director Philip Bro, involving the gifting of shares to a spouse, alongside noted recent changes in institutional holdings.

Director’s share transfer and drug pipeline updates prompt institutional repositioning

AstraZeneca reported an internal share transfer by Non-Executive Director Philip Bro, involving the gifting of shares to a spouse. The company also updated its clinical pipeline, sharing results from a mid-stage trial for AZD1163 in rheumatoid arthritis and progress in a real-world study on paroxysmal nocturnal hemoglobinuria in China. Additionally, AstraZeneca and Daiichi Sankyo have jointly applied for a second EU approval of Datopotamab Deruxtecan, and recent changes in institutional holdings were noted.

Sideways trading range as technicals reveal mixed momentum and weak conviction

The nearest support is provided by the MA-50, while resistance is indicated by the Ichimoku Kijun at GBX 13,762.00. Momentum signals are mixed: the daily MACD points to strong bullish momentum, and the ADX is supportive at 26.92, but oscillators are divergent. The RSI is in buy territory at 51.60, while Stoch RSI and Bull/Bear Power both indicate oversold or seller dominance; CCI also shows weakness. The Awesome Oscillator is neutral and does not reinforce the direction. Today's session shows a small gap up at the open (previous close: GBX 13,548.00; open: GBX 13,574.00), and the current price is in the middle of today's GBX 13,542.67 – 13,620.00 range, reflecting low intraday volatility and a mild upward bias without follow-through strength. The overall intraday tone is sideways with a slight lift after the open, but momentum signals do not universally confirm either sustained buying or selling.

High probability of narrow trading band as weekly signals support upside

For the next five trading days, the expected price range is GBX 13,400 to GBX 13,950, reflecting the typical volatility seen in this blue-chip stock and a volatility band relative to current levels. The probability of a price increase is very high (more than 80%), making a decline much less likely, based on the strong alignment of buy signals across weekly indicators. The baseline scenario sees AZN remain in a narrow sideways corridor near current values. A bullish scenario could develop if the price breaks above the GBX 13,762 resistance, while a fall below MA-50 support around GBX 13,200 may trigger a short-term pullback, though the larger trend remains positive.

Anton Kharitonov, expert at Traders Union, sees AstraZeneca moving steadily but lacking clear momentum. The stock’s technical profile shows support at MA-50 and resistance at GBX 13,762.00, with intraday signals pointing to sideways action rather than conviction. Although recent company updates are generally neutral, indicator divergence and weak oscillator readings make him cautious. "Until AstraZeneca breaks above GBX 13,762.00 or loses MA-50, I remain neutral and wait for stronger directional confirmation."

Previously it was reported that AstraZeneca PLC is showing short-term weakness below its 20-day moving average, though it maintains a medium- and long-term bullish bias by staying well above its 50- and 200-day averages. Momentum indicators such as MACD remain supportive, but mixed oscillators and resistance at the Ichimoku Kijun suggest potential for near-term consolidation within a broadly defined range, with limited downside risk and a high probability of upward movement if buying resumes.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.